RICHMOND, Va. -- In a deal that would expand the reach of one of the nation’s largest tobacco manufacturers into noncombustible products, Altria Group Inc. has invested in a Canadian developer of oral nicotine-delivery systems.
Richmond, Va.-based Altria, through a subsidiary, agreed to a research-and-development deal that could ultimately lead to a $12 million investment. Altria Ventures Inc. will pursue innovation in oral nicotine-delivery consumer products with Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience Corp., Kelowna, British Columbia.
The research will involve Lexaria’s patented technology DehydraTech, which enhances compounds in four “ingestible” categories: taste and smell, speed of action, bio-absorption and bio-availability, Lexaria officials said.
Altria will provide initial funding of $1 million, with the option of additional funding of up to $12 million through multiphased, private financing.
The deal grants Altria license to use Lexaria’s patented technology for oral nicotine delivery on an exclusive basis in the United States and a nonexclusive basis elsewhere globally.
The investment comes weeks after Altria announced it had purchased minority stakes in e-cigarette maker Juul Labs, San Francisco, for $12.8 billion and Cronos Group, a cannabis grower and producer based in Toronto, for $1.8 billion. Both moves extend the tobacco maker’s reach into new market areas.
RICHMOND, Va.—Close talks with the U.S. Food and Drug Administration (FDA), a minority stake in upstart Juul e-cigarettes and a public step into the marijuana business all happened in a matter of weeks at the tail end of 2018 and into the new year for one of the country’s largest producers of tobacco products, Altria Group Inc.
Faced with the steady decline of cigarette volume across the United States in recent years, tobacco companies like Richmond, Va.-based maker of the popular Marlboro brand of cigarettes have had to scramble to remake their destinies. But none has moved quicker in the past few weeks than Altria.
Here’s a summary of their latest moves …
Following warning letters sent by the FDA last fall to several manufacturers of electronic cigarettes and vaping devices, Altria announced plans to remove its MarkTen Elite and Apex by MarkTen pod-based vaping products until they “receive a market order from the FDA or the youth issue is otherwise addressed,” the company said in a press release.
The move is the first in what could be many steps by manufacturers as the FDA investigates marketing practices for such devices. The FDA held meetings with top manufacturers late last year and announced its intentions to call for more meetings in 2019.
Announced alongside its quarterly earnings report on Oct. 25, Altria related its actions back to the FDA’s September announcement of steps it is taking to address the problem of minors using vaping products.
On Dec. 7, Altria announcement it would discontinue the production and distribution of all its MarkTen and Green Smoke e-vapor products, as well as Verve oral nicotine-containing products. The company said its decision was based on current and expected financial performance of these products, coupled with regulatory restrictions that burden Altria’s ability to quickly improve these products. The company said it will refocus its resources on “more compelling” reduced-risk tobacco-product opportunities.
Altria signed and closed on a $12.8 billion investment in Juul Labs Inc., a San Francisco-based maker of electronic cigarettes and e-vapor products. Announced in December, the investment represents a 35% economic interest in Juul, valuing the company at $38 billion. Altria will participate in the e-vapor category only through Juul, it said.
Altria’s stated strategic rationale for the investment in Juul is that it:
- Provides a significant stake in the largest and fastest growing e-vapor company with a highly talented management team, successful in-market products and strong innovation pipeline.
- Offers exposure to strong revenue and volume growth opportunity with attractive unit economics and to significant international growth plans and global e-vapor profit pool.
- Better positions Altria with adult smokers interested in alternatives while continuing to compete vigorously in all other tobacco product markets.
Juul will remain fully independent, the companies said, but it will have access to Altria’s infrastructure and services.
In December, Altria also made a significant move in the marijuana business, entering an agreement to acquire newly issued shares in Cronos Group Inc., a Toronto-based cannabinoid company. The transaction represents a 45% equity stake in Cronos Group for an aggregate investment of approximately $1.8 billion.
Regarding its heat-not-burn product, iQOS, Altria officials said they could move the devices to market as quickly as three to four months after the FDA approves the tobacco company’s new-product application.
Members help make our journalism possible. Become a CSP member today and unlock exclusive benefits, including unlimited access to all of our content. Sign up here.